Sarcoidosis pulmonar ("la gran simuladora")

Referencias

1. Newman LS, Rose CS, Bresnitz EA, et al; ACCESS Research Group. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324-1330.
2. ACCESS Research Group. Design of a case control etiologic study of sarcoidosis (ACCESS). J Clin Epidemiol. 1999;52(12): 1173-1186.
3. Statement on sarcoidosis: joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736-755.
4. Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181(4):360-373.
5. Dubaniewicz A. Microbial and human heat shock proteins as ‘danger signals’ in sarcoidosis. Hum Immunol. 2013;74(12): 1550-1558.
6. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 1997; 156(5):1601-1605.
7. Fischer A, Rybicki BA. Granuloma genes in sarcoidosis: what is new? Curr Opin Pulm Med. 2015;21(5):510-516.
8. Grunewald J, Kaiser Y, Ostadkarampour M, et al. T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. Eur Respir J. 2016;47(3):898-909.
9. Wahlström J, Dengjel J, Persson B, et al. Identification of HLADR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest. 2007;117(11):3576-3582.
10. Clayton GM, Wang Y, Crawford F, et al. Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity. Cell. 2014;158(1):132-142.
11. Dempsey OJ, Paterson EW, Kerr KM, Denison AR. Sarcoidosis. BMJ. 2009;339:b3206.
12. Baughman RP, Teirstein AS, Judson MA, et al; Case Control Etiologic Study of Sarcoidosis  (ACCESS) Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10, pt 1):1885-1889.
13. Birnie DH, SauerWH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305-1323.
14. Ungprasert P, Carmona EM, Crowson CS, Matteson EL. Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. Lung. 2016;194(1):91-95. 
15. Furuya K, Yamaguchi E, Itoh A, et al. Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax. 1996;51(8):777-780.
16. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010;138(5):1078-1085.
17. Scadding JG. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years’ observation. Br Med J. 1961;2(5261):1165-1172.
18. Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis; a 15-year European study. Am Rev Respir Dis. 1984;130(1):29-32.
19. Spagnolo P, Sverzellati N, Wells AU, Hansell DM. Imaging aspects of the diagnosis of sarcoidosis. Eur Radiol. 2014;24(4):807-816.
20. Wong M, Yasufuku K, Nakajima T, et al. Endobronchial ultrasound: new insight for the diagnosis of sarcoidosis. Eur Respir J. 2007;29(6):1182-1186.
21. Culver DA, Costabel U. EBUS-TBNA for the diagnosis of sarcoidosis: is it the only game in town? [editorial]. J Bronchology Interv Pulmonol. 2013;20(3):195-197.
22. Agarwal R, Srinivasan A, Aggarwal AN, Gupta D. Efficacy and safety of convex probe EBUS-TBNA in sarcoidosis: a systematic review and meta-analysis. Respir Med. 2012;106(6):883-892.
23. Trisolini R, Lazzari Agli L, Tinelli C, De Silvestri A, Scotti V, Patelli M. Endobronchial ultrasound- guided transbronchial needle aspiration for diagnosis of sarcoidosis in clinically unselected study populations. Respirology. 2015;20(2):226-234.
24. Plit ML, Havryk AP, Hodgson A, et al. Rapid cytological analysis of endobronchial ultrasound-guided aspirates in sarcoidosis. Eur Respir J. 2013;42(5):1302-1308.
25. Nagai S, Izumi T. Bronchoalveolar lavage: still useful in diagnosing sarcoidosis? Clin Chest Med. 1997;18(4):787-797.
26. Mukhopadhyay S, Wilcox BE, Myers JL, et al. Pulmonary necrotizing granulomas of unknown cause: clinical and pathologic analysis of 131 patients with completely resected nodules. Chest. 2013;144(3):813-824.
27. Reich JM, Brouns MC, O’Connor EA, Edwards MJ. Mediastinoscopy in patients with presumptive stage I sarcoidosis: a risk/benefit, cost/benefit analysis. Chest. 1998;113(1):147-153.
28. Judson MA, Baughman RP, Costabel U, Mack M, Barnathan ES. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med. 2014;108(1):189-194.
29. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996;51(3):238-247.
30. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest. 1997;111(3):623-631.
31. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O; Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002;121(1):24-31.
32. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119-127.
33. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest. 1999;115(4):1158-1165.
34. Axelrod L. Glucocorticoid therapy. Medicine (Baltimore). 1976; 55(1):39-65.
35. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104(5):717-723.
36. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996; 71(1):5-13.
37. Limper AH, Knox KS, Sarosi GA, et al; American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96-128.